糖尿病多支冠脉病变血运重建术后长期生存比较
该研究基于加拿大安大略省2008至2017年数据,采用倾向性评分匹配比较糖尿病合并多支冠脉病变患者接受PCI或CABG的早期与长期结局。匹配后4301对患者中,两组早期死亡率无差异,但PCI组全因死亡和MACCE风险显著高于CABG组。
要点
- 糖尿病多支冠脉病变患者中,CABG较PCI显著降低长期全因死亡风险(HR 1.39)。
- PCI组MACCE复合终点风险约为CABG组的2倍(HR 1.99)。
- 匹配后两组早期死亡率无显著差异(2.4% vs 2.3%,p=0.721)。
核心结论
- 在糖尿病合并多支冠脉病变患者中,CABG与PCI相比与更好的长期生存和无MACCE生存相关。
研究设计与样本
- 基于加拿大安大略省临床与行政数据库的回顾性队列研究,纳入2008至2017年接受PCI或孤立CABG的糖尿病合并2或3支冠脉病变患者。
- 共4519例接受PCI、9716例接受CABG,经1:1倾向性评分匹配基于23个基线协变量生成4301对匹配患者。
主要发现
- 匹配后PCI与CABG早期死亡率无差异(2.4% vs 2.3%,p=0.721)。
- 中位随访5.5年、最长11.5年,PCI组全因死亡风险显著高于CABG组(HR 1.39;95%CI 1.28-1.51)。
- PCI组MACCE复合终点风险显著高于CABG组(HR 1.99;95%CI 1.86-2.12)。
临床怎么用
- 对于糖尿病合并多支冠脉病变患者,CABG应作为优先考虑的血运重建策略以改善长期预后。
- PCI虽早期安全性与CABG相当,但长期死亡和MACCE风险更高,决策时需综合评估。
局限性
- 原文未报告具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There remains a paucity of real-world observational evidence comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with diabetes and multivessel coronary artery disease (CAD). OBJECTIVES: This study compared early and long-term outcomes of PCI versus CABG in patients with diabetes. METHODS: Clinical and administrative databases in Ontario, Canada were linked to obtain records of all patients with diabetes with angiographic evidence of 2- or 3-vessel CAD who were treated with either PCI or isolated CABG from 2008 to 2017. A 1:1 propensity score match was performed to account for baseline differences. All-cause mortality and the composite of myocardial infarction, repeat revascularization, stroke, or death (termed major cardiovascular and cerebrovascular events [MACCEs]) were compared between the matched groups using a stratified log-rank test and Cox proportional hazards model. RESULTS: A total of 4,519 and 9,716 patients underwent PCI and CABG, respectively. Before matching, patients who underwent CABG were significantly younger (age 65.7 years vs. 68.3 years), were more likely to be men (78% vs. 73%) and had more severe CAD. Propensity score matching based on 23 baseline covariates yielded 4,301 well-balanced pairs. There was no difference in early mortality between PCI and CABG (2.4% vs. 2.3%; p = 0.721) after matching. The median and maximum follow-ups were 5.5 and 11.5 years, respectively. All-cause mortality (hazard ratio [HR]: 1.39; 95% CI: 1.28 to 1.51) and overall MACCEs (HR: 1.99; 95% CI: 1.86 to 2.12) were significantly higher with PCI compared with CABG. CONCLUSIONS: In patients with multivessel CAD and diabetes, CABG was associated with improved long-term mortality and freedom from MACCEs compared with PCI.
引用
- Tam DY, Dharma C, Rocha R, et al. Long-Term Survival After Surgical or Percutaneous Revascularization in Patients With Diabetes and Multivessel Coronary Disease. J Am Coll Cardiol. 2020. PMID: 32883408. doi:10.1016/j.jacc.2020.06.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。